摘要
目的分析治疗后慢性心力衰竭患者心功能,评估沙库巴曲缬沙坦治疗应用价值。方法选取120例慢性心力衰竭患者为研究对象,就诊时间为2021年1月-2022年12月。通过随机数字表法分组后,分别给予缬沙坦治疗、沙库巴曲缬沙坦治疗,命名为对照组、研究组(各60例)。结果治疗后,研究组左室舒张末期内径(leftventricular end diastolic diameter,LVEDD)、左室收缩末期内径(left ventricularend systolic diameter,LVESD)低于对照组,左心室射血分数(left ventricular ejection fraction,LVEF)以及心脏指数(cardiac index,CI)高于对照组,P<0.05;心功能分级分析:研究组优于对照组(P<0.05);研究组治疗有效率高于对照组,P<0.05;研究组不良反应发生率低于对照组,P<0.05。结论沙库巴曲缬沙坦的安全性、有效性高,有助于疾病的转归。
Objective To analyze the cardiac function of patients with chronic heart failure after treatment,and to evaluate the value of treatment with sarcubatrixartan.Methods 120 patients with chronic heart failure were selected from January 2021 to December 2022.Groups were divided by random number table,and then given valsartan and Shakubartrivalsartan,and named as control group and study group(60 cases each).Results leftventricular end diastolic diameter(LVEDD)and left ventricularend systolic diameter(LVESD)in study group were lower than those in control group.Left ventricular ejection fraction(LVEF)and cardiac index(CI)were higher than those in control group(P<0.05).Cardiac function grading analysis:the study group was better than the control group(P<0.05).The effective rate of the study group was higher than that of the control group,P<0.05.The adverse reactions in the study group were lower than those in the control group,P<0.05.Conclusion Sarcubatrivalsartan is safe and effective,which is helpful to the prognosis of the disease.
作者
刘伟
Liu Wei(Boshan District Hospital of Traditional Chinese Medicine,Zibo,Shandong 255200,China)
出处
《首都食品与医药》
2023年第13期59-61,共3页
Capital Food Medicine
关键词
慢性心力衰竭
心功能
沙库巴曲缬沙坦
治疗有效率
不良反应
Chronic heart failure
Cardiac function
Shakubatravalsartan
Effective rate of treatment
Adverse reactions
